Pharmaceutical News

RSS

EUSA completes BLA filing for ERWINASE in treatment of acute lymphoblastic leukemia

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ERWINASE(R) (L-asparaginase derived from Erwinia chrysanthemi) for use in the treatment of acute lymphoblastic leukemia in patients with hypersensitivity to E. coli-derived asparaginase.

9 Nov 2010

Ultrasound needle guidance improves performance and outcomes of knee injections

The use of ultrasound needle guidance improves the performance, outcomes and the cost-effectiveness of knee injections in people with osteoarthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Fake antimalarial medications uncovered across Ghana

Substandard and counterfeit versions of thirteen key antimalarial medicines were uncovered in multiple locations across Ghana by the Medicines Quality Monitoring surveillance program. Set up by the Ghana Food and Drugs Board (FDB) in collaboration with the U.S. Pharmacopeial Convention (USP) and the U.S. Agency for International Development (USAID), the program samples antimalarials across the public and private sectors.

9 Nov 2010

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Today, Intercell AG announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board.

9 Nov 2010

Combination treatment with methotrexate and prednisone achieves remission in newly-developed RA

People with newly-developed rheumatoid arthritis or undifferentiated arthritis may be able to achieve remission, with continued drug therapy, after four months of treatment with methotrexate and prednisone, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Scientists develop nanobioconjugate drug to target brain tumor

Nine years ago, scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute detected a subtle shift occurring in the molecular makeup of the most aggressive type of brain tumors, glioblastoma multiforme. With further study, they found that a specific protein called laminin-411 plays a major role in a tumor's ability to build new blood vessels to support its growth and spread. But technology did not exist then to block this protein.

9 Nov 2010

Cook Medical's controlled-release esophageal stent receives FDA clearance

Cook Medical's controlled-release esophageal stent fully covered in silicone has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), making available yet another advanced solution from Cook Medical, the only full-line supplier of endoscopic devices.

9 Nov 2010

EpiCept third quarter net loss decreases to $3.2 million

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2010, and provided an update with respect to the Company's key business initiatives.

9 Nov 2010

Epeius receives competitive grant to support Rexin-G oncology product

Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, announced today the receipt of additional financial support for the company's lead oncology product, Rexin-G, from the U.S. Departments of Treasury, Health and Human Services (HHS), and the National Institutes of Health (NIH) in the form of a prestigious competitive grant.

9 Nov 2010

CMS to review cancer vaccine, analysis shows high Medicare drug spending not correlated with better care

The Centers for Medicare & Medicaid Services are conducting an unusual review to determine whether the government should pay for an expensive new vaccine for treating prostate cancer, rekindling debate over whether some therapies are too costly.

9 Nov 2010

Advaxis collaborates with UBC to develop live attenuated Listeria vaccines

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has entered into a structured collaboration with the laboratory of Dr. Tobias Kollmann at the University of British Columbia (UBC) to develop live attenuated Listeria vaccines for the treatment of infectious disease and for new dosage forms of Listeria vaccines.

9 Nov 2010

Teens abuse prescription drugs more than illegal drugs

According to the 2006 National Survey on Drug Use and Health, teens abuse prescription medications more than all illegal drugs combined, excluding marijuana. Many teens are under the misconception that these highly addictive, easily accessible drugs are "safer" than illicit drugs.

9 Nov 2010

Study finds anti-gout medication may reduce risk of colorectal cancer

Allopurinol, a relatively inexpensive anti-gout medication that has been on the market for more than 20 years, may have some activity against colorectal adenomas, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held here Nov. 7-10, 2010.

8 Nov 2010

Gents renews distribution agreement for AcnEase with Herborium

Herborium Group, Inc., a Botanical Therapeutics™ company, during its shareholder conference call yesterday afternoon, announced that Gents, AB of Helsingborg, Sweden, renewed its distribution agreement to supply AcnEase® throughout Sweden.

8 Nov 2010

Blocking beta glucuronidase enzyme could eliminate side effects of CPT-11 in colon cancer treatment

A debilitating side effect of a widely used but harshly potent treatment for colon cancer could be eliminated if a promising new laboratory discovery bears fruit.

8 Nov 2010

Vapor rub improves sleep for children with cold symptoms

Applying a vapor rub is effective for treating children with night-time cough and congestion and improves sleep for children with cold symptoms, according to Penn State College of Medicine researchers.

8 Nov 2010

Apricus receives $733,437 grants under QTDP program

Apricus Biosciences, Inc., today announced the award of three grants totaling $733,437 under the Qualifying Therapeutic Discovery Project program for PrevOnco, RayVa and Femprox which are the Company's development programs in cancer, autoimmune/cardiovascular and female sexual dysfunction, respectively.

8 Nov 2010

Hydroxychloroquine may reduce cardiac neonatal lupus in subsequent pregnancies: Research

Women with anti-SSA/Ro antibodies and a previous child who has heart block a condition where the electrical signal that makes the heart beat is damaged may potentially decrease their risk of delivering another child with life threatening heart disease by taking hydroxychloroquine (Plaquenil), according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Statin drugs do not benefit pediatric lupus patients

Lupus puts children at higher risk for coronary artery disease when they become adults, but routinely using statins doesn't provide enough benefit to warrant their regular use in children and adolescents, according to the largest study of pediatric lupus patients to date.

8 Nov 2010

Amgen wins Scrip Best New Drug award for Prolia

Amgen is pleased to announce that it has won the Best New Drug award for Prolia™ (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the 2010 Scrip Awards ceremony Nov. 4 in London. Named one of TIME's Top 10 Medical Breakthroughs of 2009, Prolia is the first treatment specifically designed to target osteoclasts, the cells that break down bone.

8 Nov 2010

Pharmaceutical News

EUSA completes BLA filing for ERWINASE in treatment of acute lymphoblastic leukemia

Ultrasound needle guidance improves performance and outcomes of knee injections

Fake antimalarial medications uncovered across Ghana

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Combination treatment with methotrexate and prednisone achieves remission in newly-developed RA

Scientists develop nanobioconjugate drug to target brain tumor

Cook Medical's controlled-release esophageal stent receives FDA clearance

EpiCept third quarter net loss decreases to $3.2 million

Epeius receives competitive grant to support Rexin-G oncology product

CMS to review cancer vaccine, analysis shows high Medicare drug spending not correlated with better care

Advaxis collaborates with UBC to develop live attenuated Listeria vaccines

Teens abuse prescription drugs more than illegal drugs

Study finds anti-gout medication may reduce risk of colorectal cancer

Gents renews distribution agreement for AcnEase with Herborium

Blocking beta glucuronidase enzyme could eliminate side effects of CPT-11 in colon cancer treatment

Vapor rub improves sleep for children with cold symptoms

Apricus receives $733,437 grants under QTDP program

Hydroxychloroquine may reduce cardiac neonatal lupus in subsequent pregnancies: Research

Statin drugs do not benefit pediatric lupus patients

Amgen wins Scrip Best New Drug award for Prolia

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News